Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,208.84 +36.69 (+0.45%) Bitcoin USD
61,727.92 +2,575.44 (+4.35%) CMC Crypto 200
1,327.97 +50.99 (+4.00%)
Rallybio Corporation (RLYB)
| Previous close | 1.8300 |
| Open | 1.8700 |
| Bid | 1.7800 x 400 |
| Ask | 1.8700 x 200 |
| Day's range | 1.8000 - 1.8700 |
| 52-week range | 1.2250 - 9.1400 |
| Volume | |
| Avg. volume | 1,636,033 |
| Market cap | 75.85M |
| Beta (5Y monthly) | -1.64 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.8400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 13.00 |
Business WireFNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
NEW HAVEN, Conn., April 17, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the presentation of results from a fetal and neonatal alloimmune thrombocytopenia (FNAIT) systematic literature review and meta-analysis at the Academy of Managed Care Pharmacy (AMCP) 2024 Annual Meeting, which is taking place in New Orleans
ZacksRallyBio (RLYB) Partners With J&J & Gets $6.6M Funding, Stock Up
RallyBio (RLYB) gains 83% after announcing a collaboration deal with J&J to develop novel therapies to reduce the risk of FNAIT in pregnant women, along with funding of $6.6 million from the latter.
Business WireRallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
NEW HAVEN, Conn., April 10, 2024--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced a collaboration with Johnson & Johnson1 to support the development of complementary therapeutic approaches aimed at reducing the risk of fetal and neonatal alloimmune thrombocytopenia (FNAIT). In addition, Rallybio received an equity investm
